Table 3.
Adjusteda hospitalization and mortality percentages of FMCHP patients and the 2007 ESRD CPM sampleb at 1 year, among patients with the indication for ONS use (analyses based on ONS indication)
| Hospitalizationc | Mortalityd | |
|---|---|---|
| FMCHP patients with average serum albumin <3.8 g/dl within 2 mo of enrollment (n=417)e | 71.8 (66.1, 76.6) | 16.2 (11.8, 20.3) |
| ESRD CPM patients with average serum albumin <3.8 g/dl in November/December 2006 (n=2425) | 72.2 (70.0, 74.3) | 23.4 (21.2, 25.4) |
Data are expressed as percentages (95% confidence intervals). FMCHP, Fresenius Medical Care Health Plan; ESRD CPM, CMS ESRD Clinical Performance Measures Project; ONS, oral nutritional supplements; CMS, Centers for Medicare and Medicaid Services.
Adjusted to the FMCHP study sample; adjusted for age at enrollment, race, Hispanic ethnicity, years since ESRD onset at enrollment, and diabetes as a comorbidity.
Data are from 2006 to 2008 for FMCHP and from 2007 for the ESRD CPM sample.
P=0.88. Significant differences between the survival estimates for FMCHP patients and CPM patients were tested using a z test.
P<0.01. Significant differences between the survival estimates for FMCHP patients and CPM patients were tested using a z test.
In this analysis, the FMCHP analysis population (n=417) is smaller than the analysis population used in Table 2 (n=470). In this analysis, the population was determined using data from the CMS Member Beneficiary Database, whereas the population in the other analysis was determined using FMCHP’s enrollment data.